(Colorectal Cancer) Zaltrap Drug Information
Medical Supporter — إشعار معلوماتي
هذه المقالة ملخص لمعلومات طبية دولية وليست نصيحة طبية، ولا يمكن أن تحل محل تشخيص طبيبك المعالج أو خطة العلاج. المعلومات المعروضة مجمّعة من منشورات عامة وبيانات رسمية لكبرى المؤسسات الطبية اليابانية؛ وتختلف ملاءمة ونتائج أي علاج من مريض لآخر ويجب أن يقيّمها طبيب مؤهل لكل حالة على حدة.
On March 30, 2017, SANOFI received manufacturing and marketing approval for Aflibercept (Zaltrap) intravenous injection 100 mg and 200 mg. It is indicated for patients with unresectable, progressive or recurrent colorectal cancer. It is used in combination with Irinotecan Hydrochloride Hydrate, Levofolinate Calcium, and 5-FU (FOLFIRI), administered every two weeks at 4 mg/kg via 60-minute intravenous infusion (dose adjustments may be made based on patient condition).
Colorectal cancer accounts for a significant proportion of cancer cases in Taiwan and Japan. Current standard treatments typically combine VEGF (Vascular Endothelial Growth Factor) inhibitors such as Aflibercept and Bevacizumab with EGFR (Epidermal Growth Factor Receptor) inhibitors such as cetuximab and panitumumab as targeted molecular therapy.
In the overseas Phase III clinical trial for metastatic colorectal cancer patients (VELOUR), Aflibercept (Zaltrap) was confirmed to be effective. It was the first VEGF inhibitor to show extended OS in the VELOUR study using oxaliplatin (Eloxatin) as first-line treatment combined with FOLFIRI.
Internationally, Zaltrap was approved in the United States in August 2012, in the EU in February 2013, and has since been approved in over 70 countries and regions worldwide as of March 2017. In Japan's domestic clinical trials, major adverse events requiring attention included neutropenia (77.4%), loss of appetite (74.2%), diarrhea (67.7%), fatigue (61.3%), and nausea (58.1%). More serious adverse events included hemorrhage, gastrointestinal perforation, fistula, hypertension, and hypertensive crisis (including hypertensive urgency and hypertensive emergency). Please consult your healthcare provider before using this medication.
*Hypertensive crisis: http://big5.wiki8.com/gaoxueyaweixiang_109003/
Drug information: https://e-mr.sanofi.co.jp/products/zaltrap
Drug precautions: https://goo.gl/3idYhI
Press release source: https://www.goo.gl/A9utl2
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
هل تفكر في تلقّي العلاج في اليابان؟ هل تحتاج إلى معلومات ومساعدة؟
نساعدك في تنظيم المعلومات اللازمة للسفر الطبي إلى اليابان، والتواصل مع المؤسسات الطبية اليابانية، وترتيب استشارة رأي ثانٍ.الاستشارة الأولى مجانية؛ سيساعدك المستشار على توضيح الخطوات التالية.
Figure 1
Figure 2
Figure 3
Figure 4